Becton Dickinson
Babson Diagnostics Prepares for Broader Commercialization of Blood Collection System in 2025
Premium
The firm has developed a fingertip blood collection device that can be used in multiple healthcare settings.
Top Five Articles on 360Dx Last Week: Becton Dickinson's Spinoff Plans; More
Last week, readers were most interested in a story about BD's plan to separate its Biosciences and Diagnostics Solutions business by the end of 2026.
Becton Dickinson to Spin Off Biosciences and Diagnostics Business as Q1 Revenues Grow 10 Percent
Premium
The separation is planned to be completed by the end of 2026 with the rest of the company transforming into a pure play medical technology firm.
Becton Dickinson Board Authorizes Repurchase of up to 10M Shares
The firm said it has repurchased $750 million dollars of its stock to date in its fiscal 2025.
Abbott, BioMérieux, Cepheid, Roche, Others Gain FDA 510(k) Clearances in December
The FDA granted marketing clearances for infectious disease tests, updates to a digital pathology system, and immunoassays for chronic diseases.